SEC Comment Letter 0000000000-25-000067 to Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: Jan. 3, 2025 · CIK: 0001708331 · Accession: 0000000000-25-000067
AI Filing Summary & Sentiment
File numbers found in text: 333-284089
Letter
January 3, 2025 Jatinder Dhaliwal Chief Executive Officer Virpax Pharmaceuticals, Inc. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 Re:Virpax Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 30, 2024 File No. 333-284089 Dear Jatinder Dhaliwal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ross D. Carmel, Esq.
Show Raw Text
January 3, 2025
Jatinder Dhaliwal
Chief Executive Officer
Virpax Pharmaceuticals, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
Re:Virpax Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 30, 2024
File No. 333-284089
Dear Jatinder Dhaliwal:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ross D. Carmel, Esq.